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ABSTRACT 
  
PATRICK PIERCE BODDIE: Purification Protocol Development and Analysis of 
Binding Properties of Calmodulin Collagen-Like Protein. 
(Under the direction of Dr. Susan Pedigo) 
  
  
 Calmodulin is an intensely studied, intracellular, calcium-binding protein that is 
involved in diverse physiological processes. When bound to calcium, calmodulin 
undergoes a conformational change that allows it to bind specific target peptides with 
high affinity, one being the calmodulin binding region of myosin light chain kinase, 
herein called M13. This high affinity, calcium dependent association has made it a 
desirable choice for use in a biomaterial for drug delivery for non-steroidal anti-
inflammatory drugs (NSAIDs). Two artificial genes have been designed by our lab for 
use in the proposed biomaterial: calmodulin collagen-like protein (CCLP), a construct 
composed of two calmodulin genes connected with a gene coding for three repeats of a 
short collagen sequence; and PCLP, a construct composed of two repeats of M13 
connected with same collagen repeats. Mixture of the two recombinant protein products 
should form a gel in the high extracellular calcium concentration found in vivo. In order 
to establish the viability of this novel biomaterial, we had to establish 1) protocols for 
expression and purification of CCLP, and 2) whether or not the calmodulin regions of 
CCLP retained their calcium-dependent binding of M13. In order to proceed with 
experimentation, a consistent protocol for the production and purification of the CCLP 
protein was developed. Confirmation of purity and concentration was obtained with SDS-
PAGE and UV-Visible spectroscopy, respectively. Second, because M13 undergoes a 
change in secondary structure upon binding, CCLP’s interaction with M13 was 
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monitored via circular dichroism spectroscopic studies. Results of these studies indicate 
that we have an efficient expression and purification protocol for CCLP, and that CCLP 
binds calcium and M13 according to its design. 
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INTRODUCTION 
 
1. APPLICATION 
 
 Inflammation is a beneficial process that the human body uses to remove 
damaged tissues and destroy foreign intruders1. Inflammatory markers, or prostaglandins, 
are paracrine hormones released by damaged tissues to recruit immune cells and increase 
blood flow to the location of diseased tissue. Temporary pain, swelling, and local 
acidification normally accompany this cascade of events, subsiding once the damage has 
been repaired or cleared. Chronic inflammation, however, is an abnormal autoimmune 
response where prostaglandin signaling is unwarranted and causes damage to healthy 
body tissues, leading to disease2.   
Chronic inflammation has been linked to the development of many serious 
conditions such as diabetes3, cancers4, cardiovascular disease, and different 
neurodegenerative disorders5. Because pain is a common symptom of chronic 
inflammation, those suffering from the disorder often rely on nonsteroidal anti-
inflammatories (NSAIDs) for relief6. NSAIDs, also known as COX-1 or COX-2 
inhibitors, are taken orally and circulate systemically to inhibit cyclooxygenase (COX), 
the first enzyme in the pathway to the production of prostaglandins7. While COX 
inhibitors are an effective treatment for chronic inflammation, the prostoglandins they 
produce serve another important role in human physiology; they are vital to the 
maintenance of the protective mucosal layer of the gastrointestinal (GI) tract8. Prolonged, 
systemic delivery of COX inhibitors disrupts the GI tract’s ability to maintain its 
protective mucosal layer and ultimately leads to ulcers and other gastrointestinal 
ailments9, 10. The purpose of our work is to develop a bio-compatible material that will be 
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assembled and embedded in vivo at the site of chronic inflammation. The proposed 
biomaterial will be covalently modified with NSAIDs through hydrolysable linkages to 
allow in situ delivery of COX inhibitors at the site of inflammation. This is beneficial 
because it will allow the drug to take effect locally in much lower doses, and will 
dynamically respond to the acidification of tissues seen during the inflammatory 
process11. These advantages will potentially allow long term use of NSAIDs with much 
lower risk of the harmful side-effects. 
 
2.  CALMODULIN AND M13 
 
 Calmodulin (CaM) is a ubiquitous, intracellular protein that regulates the activity 
of many target enzymes. A few of its many regulatory roles include the contractile state 
of smooth muscle12, short and long-term potentiation in neurons13, and lipid 
metabolism14. CaM, a natural intracellular protein, was chosen as the basis for the 
biomaterial for three primary reasons. First, high affinity for binding specific ligands 
allows the development of two independent protomers, one with CaM and the other with 
a peptide binding partner, M13, that will interact specifically to create the gel matrix. 
Second, its calcium-dependent function will allow assembly of the biomaterial in the high 
calcium concentrations in the extracellular (EC)- space. Third, its resilience towards its 
chemical environment will allow chemical modification of the CaM-based component for 
the purpose of covalent modification with drugs. In the remainder of this section, 
calmodulin and M13, the CaM-binding component from myosin light chain kinase, will 
be discussed in detail. 
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Calcium Response 
 Calcium signalling occurs due to large intracellular transmembrane gradients that 
exist between the endoplasmic reticulum and the cytosol, or between the EC-space and 
the cytosol; extracellular concentrations [1mM]15 far exceed intracellular cytosolic 
concentrations [0.0001mM]16. Within the cell, calcium acts as a secondary messenger for 
signal transduction pathways that are triggered when intracellular calcium levels are 
increased by the opening of voltage gated ion channels or by release from the 
endoplasmic reticulum within the cell. CaM works as the intracellular calcium sensor, 
controlling the activity of enzymes in response to stimuli. 
 Four calcium ions bind to CaM’s four binding sites, located between residues 21-
32 and 57-68 in the N-terminal domain, and between residues 94-105, and 130-141 in the 
C-terminal domain17. The binding of four calcium ions to the N- and C-terminal EF-hand 
sites causes conformational change that exposes hydrophobic surface areas in each 
domain. This conformational change increases CaM’s binding affinity for its target 
proteins18. CaM’s specific, high affinity, calcium dependent association with peptides 
resulting from its normal intracellular targets makes it ideal for use in biomaterials in the 
high calcium environment of the EC-space. 
 
Ligand Binding to M13 
 CaM’s ability to bind many different targets is due to noncovalent interactions. 
The interaction of CaM with myosin light chain kinase (MLCK) has been thoroughly 
studied. During contraction in skeletal muscle, calcium-bound CaM activates MLCK via 
its CaM binding site. This CaM binding site contains residues 577-602 of MLCK, a 26 
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residue segment called M13. Once CaM interacts with M13, M13 undergoes a 
conformational change from random coil to α-helix and CaM becomes more compacted 
as it wraps around the now helical peptide19.  
 This change in secondary structure of both the peptide and CaM will be exploited 
in monitoring the interaction between CCLP and M13. Figure 1 illustrates the binding of 
Ca2+ to CaM, and subsequent association with one of its physiological binding partners. 
 
 
 
FIGURE 1: The Structure and Function of Calmodulin.  
 
[Left] (A) Ribbon drawing of calmodulin with calcium binding regions (yellow). Two 
EF-hand sites are located at  the N-domain (blue), and two at the C-domain (red). The 
central helix is disordered at the intersection of the two domains (black). (B) When 
bound to calcium, the hydrophobic surface areas (orange) are exposed. (C)  Ribbon 
drawing of calmodulin binding a physiological partner (green). (D) Cartoon drawing of 
interaction between calmodulin and its binding partner, showing the hydrophobic 
surface areas interact.  
[Right] Alignment of Calcium Binding Sites: EF-hand sites contain 12 residues, 6 of 
which directly chelate calcium (red): five (X, Y, Z, -X, and –Y) offer one carbonyl 
oxygen to chelate calcium; one (-Z) is a bidentate chelator of calcium. Consensus 
sequence highlights the conserved residues. There are only 2 tyrosines and 4 serines and 
no cysteine or tryptophan residues in CaM. 
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Resilience of Calmodulin to Denaturation 
 CaM has two globular domains connected by a long central helix. As such, it has 
more accessible surface area than a spherical protein. It is soluble in high concentration 
and renatures when heat denatured or chemically denatured20. The best example of its 
resilience to permanent denaturation is the protocol for its purification from tissue12. The 
resilience of CaM makes it easy to purify from complex mixtures and enhances its ability 
to withstand modification by organic reactions. 
 
3. CCLP and PCLP 
 CCLP and PCLP are the protein constructs we designed for use in the proposed 
biomaterial. These two constructs, respectively, incorporate repeats of CaM and M13 into 
complex protomers of our particular design (Figure 2). The concept is that mixing of 
these protomers in the EC-space in vivo will create a vast, multi-protomer 3D matrix 
upon exposure to the high calcium environment that is the EC-space.  
 
Figure 2: Design Concept of the CCLP and PCLP Constructs.  
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(Figure 2 continued) A HisTag is at the N-terminus to simplify the purification 
process. Two CaM repeats are linked in an alternating sequence with a collagen linker 
sequence (CLS). These CLS regions contain serine and tyrosine residues for 
modification and collagenase cleavage sites. A cysteine (Cys) residue is at the C-
terminus to allow disulfide linkages between protomers or to insert specers.  [Bottom] 
A layout of the PCLP construct. M13 regions will be bound by the CaM regions of the 
CCLP construct. *Dimensions are not to scale. 
 
CCLP Domains 
 The amino acid sequence of the CCLP construct is described in detail in Figure 3. 
The HisTag sequence present at the N-terminus allows for purification via HisTag 
chromatography. HisTag chromatography is a simple and reliable method used to purify 
genetically engineered proteins. We expect the CaM sequences in CCLP perform the 
same binding function as their isolated form. Making this protein from a synthetic gene, 
purifying it and ensuring that the CaM sequences bind peptide are the goals of this 
project. 
 The CLS regions are composed of three short collagen repeats separated by 
glycine (G), tyrosine (Y), and serine (S) residues (GSGYG). Tyrosine and serine residues 
in the CLS region and those in the CaM sequences are the targets of the drug attachment 
process described briefly below. The CLS contains a collagenase cleavage site 
(GPQG/IWGQ) that was chosen since it is substrate for collagenases secreted by 
inflamed tissues21. The choice to include 3 repeats of the CLS sequence was made so that 
the CaM sequences would be separated in the final gel to eliminate crowding between 
interacting protomers. A single cysteine residue, located at the C-terminus, will allow the 
formation of disulfide linkages to occur between identical protomers thereby doubling the 
numbers of CaM or M13 interaction sites in a protomer from 2 to 4.  Additionally, spacer 
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molecules such as divinyl sulfone polyethylene glycol can be inserted between protomers 
to further diversify the structural capabilities of the proposed biomaterial.  
 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSMADQLTEE
QIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDM
INEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKD
GNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYE
EFVQMMTAKELQGPQGIWGQGSGYGGPQGIWGQGSGYGGPQ
GIWGQGRRSGYGGSMADQLTEEQIAEFKEAFSLFDKDGDGTITT
KELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMM
ARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKL
TDEEVDEMIREADIDGDGQVNYEEFVQMMTAKELQGPQGIWGQ
GSGYGGPQGIWGQGSGYGGPQGIWGQGSGYGRSC  
Figure 3: CCLP Amino Acid Sequence. 
 
The HisTag region (grey) is composed of His6 for HisTag chromatography. Each CaM 
sequence (blue) provides calcium dependent binding activity to the construct. 
Collagenase cleavage sites (green) are separated by the modification sequences 
(underlined). The cysteine residue (red) will allow disulfide linkage to occur between 
constructs in order to further diversify potential matrix structures. 
 
Modification of CCLP with NSAIDs 
 The 23 serine (S) residues and 10 Tyrosine (Y) residues present in the CCLP 
construct will be the targets for modification with NSAID drugs. There are also 17 amine 
residues that have the potential to be modified during the process. These modifiable 
residues are located on the surface of the CaM repeats and within the exposed 
modification sequences of the CLS region. Figure 4 shows the structure of Aspirin and 
Naproxen, the two NSAIDs that will be used to modify the constructs. Hydrolysis of ester 
linkages is increased in acidic environments22.  
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Figure 4: Aspirin and Naproxin. 
 
[Left] The structure of Aspirin. [Right] The structure of Naproxin. Ester or amide linkage 
to CCLP will be made at the hydroxyl group of each carboxylic acid. 
 
Responsive Biomaterial 
 Because of their design, CCLP and PCLP will bind in a way that forms a vast, 
random 3D matrix. Figure 5 illustrates just one of the many ways that the two constructs 
may associate. Disulfide linked protomers will double the number of “nodal” sites from 2 
to 4 for interacting protomers. 
 
Figure 5: Illustration of “Gel” Matrix Formed by CCLP and PCLP Interaction. 
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(Figure 5 continued) This illustrates the association of CCLP with PCLP into a matrix 
upon exposure to high EC Ca2+ in vivo. While the matrix depicted is uniform, many 
possible patterns of association between the two constructs can exist. 
 
 Once placed in the inflamed region of the body, the inflammatory process will 
speed the release of drug and the breakdown of the matrix. The low pH created by the 
inflamed tissue will drive the hydrolysis of NSAID molecules from modified residues. 
Collagenases will break down the matrix by cleaving the sites located within the CLS 
region of the construct. When inflammation is lessened due to NSAID release, pH will 
increase, and the gel will stabilize; cleavage of the ester linkages and the activity of the 
collagenases will decrease.   
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EXPERIMENTAL PROCEDURES 
 
 
EXPERIMENT 1: Overexpression and Purification of CCLP in BL21(DE3) E. Coli. 
 The first goal of my research was to confirm that the CCLP construct can be 
expressed in E. Coli and purified. Figure 6 shows a summary of the procedure that was 
established. This section will describe the specifics of the components of this protocol.  
 
Figure 6: Summary of Transformation, Overexpression and Purification Procedures. 
 
This flowchart illustrates a summary of the developed protocol for the production and 
recovery of purified CCLP. 
 
Plasmid Design 
 Figure 7 shows the mechanism for the bacterial production of the CCLP protein 
construct. A plasmid containing the designed CCLP gene was transformed into 
BL21(DE3) E. Coli. The cell line contains the gene for T7 polymerase following a lac 
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promoter that is inducible by IPTG. The CCLP gene is placed following a T7 promoter 
region. Once transcribed and translated, T7 polymerase attaches to the T7 promoter 
region of the plasmid and transcribes the CCLP gene. Expression cell lines containing the 
plasmid are frozen in dilute glycerol solutions so that transformed cells are readily 
accessible.  
 
Figure 7: Detailed Mechanism of the CCLP Plasmid. 
IPTG (red) derepresses the lac promoter (blue) present in the chromosomal DNA of 
BL21(DE3) E. Coli. This causes the production of T7 Polymerase (green). T7 
Polymerase then binds to the T7 promoter region (orange) of the plasmid and transcribes 
the CCLP gene, producing CCLP mRNA (yellow). The Kan region (pink) contains a 
gene that confers resistance to the antibiotic kanamycin, allowing for the selection of 
successfully transformed cells. 
 
LB Agar Plates 
Day 1: LB Agar plates with and without 30µg/mL kanamycin and liquid media were 
prepared. In two 250mL Erlenmeyer flasks, 100mL of water, 2g tryptone, 1g yeast 
extract, 1g NaCl, and 1.5g agar were combined and autoclaved. Once cooled to ~600C, 
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100µL of kanamycin stock (30mg/mL) was added to one plate. Five plates were poured 
from each flask. These plates are used to streak cells from the frozen stocks of 
transformed expression cell lines. 
LB Liquid Cultures 
Day 1: One 50mL sterile LB culture was prepared in a 250mL Erlenmeyer flask. 50mL 
water, 1g tryptone, 0.5g yeast extract, and 0.5g NaCl were combined and autoclaved. 
Three 1L LB cultures were then prepared and autoclaved in 2.5L Fernbach flasks 
comprising 1L water, 20g tryptone, 10g yeast extract, and 10g NaCl. 
Preparation of Colony 
Day 1: Pre-transformed cells from the deep freezer were streaked onto two sterile plates 
(LB and LB+Kan) with inoculation loop. They were incubated overnight at 37˚C. 
Preparation of Overnight Culture 
Day 2: A volume of 50µL of Kan stock was added to one 50mL LB culture. One colony 
from the LB+Kan plate was taken with an inoculating loop used to inoculate the 50mL 
LB+Kan culture. The inoculated culture was placed in the incubator at 37˚C with shaking 
at 200rpm overnight.  
Overexpression of CCLP 
Day 3: A volume of 20mL 20% Glucose, 50mL of 1M potassium phosphate, 5mL of 
overnight culture and 1mL kanamycin stock was added to each of the three 1L LB 
cultures. They were placed on the rotating incubator at 37˚C at 200rpm. Cell growth was 
monitored with UV-Visible spectrophotometer (Cary 50 Bio UV-Visible 
Spectrophotometer) with absorbance set at 600nm and blanked against LB culture only. 
Once at mid-log phase (0.6AU; this usually takes ~5 to 6hrs), a 1mL sample was placed 
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in a labelled eppie, centrifuged (Fisher Scientific Micro Centrifuge Model 235C), 
supernatant was decanted and the pellet was placed on ice. This sample is the pre-
induction sample for SDS-PAGE analysis. Then, a 1mL volume of 0.4M IPTG stock was 
added to each 1L culture to induce expression of T7 RNA Polymerase and CCLP. We 
waited 2hrs to allow bacteria to produce the CCLP. After 2hrs, the post-induction sample 
was taken for a gel and frozen. The 1L culture were transferred into 1L centrifuge bottles 
and centrifuged (Sorvall 5B Centrifuge) at 3000rpm for 15min at 40C. Supernatant was 
decanted, pellets combined by suspension in 10mL of 20mM HEPES, 100mM KCl pH 
7.4 buffer and frozen overnight. 
Sonication and Pelleting of Cell Debris  
Day 4: Thawed cells were transferred to a 200mL stainless steel beaker, and placed on 
ice. Sonication with a blunt tip (2mins, 5sec pulse, 50% power) lysed cells, and a post-
sonication sample was removed for gel analysis. Sonicated cells were transferred into 
Oakridge tubes and centrifuged (Sorvall 5B Centrifuge) at 12,000rpm, 4˚C for 45mins. 
Supernatant was transferred into 100mL graduated cylinder, and a sample was taken for a 
gel. The pellet was saved until the process was completed. 
Heat Treatment of Supernatant 
Day 4: The supernatant was brought to a final concentration of 50mM calcium, placed 
into a water bath at 800C for 10mins, and then placed on ice for 10mins. Cold supernatant 
was transferred into Oakridge tubes and centrifuged at 12,000rpm, 40C for 20mins. 
Samples of supe and pellet were placed in eppies for a gel. 
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Dialysis into HisTag Binding Buffer and Preparation of Chromatography Column 
Day 4: Supernatant was transferred into 8,000 MWCO dialysis tubing and dialyzed for 
24hrs against 1L of binding buffer (see composition below) in preparation for HisTag 
chromatography. Buffer was exchanged after 12hrs. 
HisTag Chromatography 
Day 5: HisTag chromatography utilizes Nickel (II) ion stationary phase (Thermo 
Scientific HisPur Ni-NTA Resin) that binds to the lone pairs present in the histidine 
residues at pH levels above the pKa for their side chain hydrogens (pKa= ~6). 
Chromatography buffers were prepared as follows: 1L Binding Buffer (0.02M Tris/HCl, 
0.50M NaCl, 0.005M Imidazole, pH 7.9), 1L Wash Buffer (0.02M Tris/HCl, 0.50M 
NaCl, 0.040M Imidazole, pH 7.9), and 1L Elution Buffer (0.010M Tris/HCl, 0.250M 
NaCl, 0.5M Imidazole, pH 7.9). The column was then equilibrated with binding buffer. A 
10mL volume of dialyzed supernatant was loaded onto the column and flow through was 
collected in 15mL conicals. Protein was purified by application of 20mL binding buffer, 
20 mL wash buffer, and 30mL elution buffer. All eluent was collected in 5 mL fractions 
and assayed by UV visible spectroscopy in 2mm path length quartz cuvette to assess 
concentration and to determine if protein has eluted properly. Samples were collected 
from fractions that contained protein for assaying by SDS-PAGE. If more dialyzed 
supernatant remains, this chromotography process is repeated.  
Dialysis and Lyophilization 
Day 6-7: Fractions containing purified protein were combined and transferred into 3-5kD 
dialysis tubing and dialyzed against 1L water for 4hrs, and repeating six times while 
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exchanging the water. The dialysate was frozen in a 50mL conical using an 
acetone/ethanol bath and lyophilized to recover solid product. 
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EXPERIMENT 2: Analysis of Binding of CCLP with M13 via Circular Dichroism 
Spectroscopy. 
 CD spectroscopy is used to see the optical activity of asymmetric compounds, and 
allows one to view the secondary structure of proteins. Each secondary structure gives a 
unique signal. When analyzed with CD, CaM emits a strong alpha helical signal with a 
distinct double minima that is characteristic of proteins that are predominantly helical. 
This double minima can also be viewed in the CCLP construct. While unbound to CaM, 
M13 assumes a random coil secondary structure. Once bound, M13 undergoes a 
conformational change and organizes into an alpha helical secondary structure. Hence, 
this change in the secondary structure of M13 upon association with the CaM regions of 
CCLP was observed with CD spectroscopy and provides evidence of their interaction. 
 The absorbance value of CD spectroscopy can be defined as the the difference 
between the absorption of left–handed circularly polarized light (LCP) and right—handed 
circularly polarized light (RCP). LCP and RCP are directed through a solution of the 
protein in question, and excite electrons in a direction opposite of the photons, creating a 
measurable magnetic moment. When interpreting a CD spectrum, rather than referencing 
absorbance at a specific wavelength, secondary structure is determined by viewing the 
absorbance trend over a range of wavelengths. Each general secondary structure exhibits 
its own graphical shape. Figure 8 contains examples of these secondary structure 
graphical shapes. 
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Figure 8: Example Secondary 
Structure CD Spectra. 
 
Each of the major secondary 
structures can be identified by their 
signature CD spectra. When 
monitoring alpha helical responses, 
the stronger the minima, the greater 
the content of alpha helices present 
in the protein subject. Since M13 
assumes alpha helix shape when 
bound, this was used to determine if 
CCLP binds M13.  
 
*Figure taken from  
http://www.ap-lab.com/circular_dichroism.htm 
 
 
CD Spectroscopic Study on CCLP 
The CCLP solution recovered from HisTag chromotography was dialyzed against 1L 
SEC buffer (10mM HEPES, 140mM NaCl).  The concentration of the protein stock was 
then adjusted to 50µM. Three solutions of 50µM CCLP stock were prepared: Apo CCLP 
(CCLP stock with 1 mM EDTA); CCLP+Ca2+ (CCLP stock, 1mM Ca2+); and 
CCLP+Ca2++M13 (CCLP stock, 1mM Ca2+, M13). A solution of M13 peptide was also 
prepared. Each solution was analyzed with a CD Spectrophotometer (Aviv Instruments 
Model 202SF) by taking spectra between 200 to 300 nm, 1 nm increments, 5sec 
averaging time. Temperature was ~ 25°C. Recovered data was parsed into Microsoft 
Excel to produce a graph. 
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RESULTS 
 
Experiment 1: Overexpression and Purification of CCLP in BL21 (DE3) E. Coli. 
The progress of experiment 1 was tracked with SDS-PAGE to assess the success of each 
of the expression and purification steps (Figure 9). This method was used to judge the 
purity of the CCLP solutions through each of the successive procedures. The molecular 
weight of CCLP is 46.2 kD. Migration can be influenced by the presence of Ca2+ in 
solution, although migration of the CCLP construct was consistent with its calculated 
MW. 
 
FIGURE 9: SDS-PAGE Analysis of CCLP Purification Process. 
 
Lane 1 in each gel are molecular weight ladders (Fisher EZ-run Protein Marker). The 
CCLP construct is 46.2 kD. The thick band present near the third band of the ladder is the 
CCLP construct. [A] (2A) Pre- and (3A) post-induction of 1L cultures with IPTG. [B] 
(2B) Pellet and (3B) supernatant post sonication. [C] Supernatant (2C) pre and (3C) post 
heat treatment at 800C with 1mM Ca2+. [D] (2D) Pure CCLP recovered from HisTag 
chromatography.  
 
Gel A of Figure 9 shows transformed BL21(DE3) E. Coli before (2A) and 2hrs 
after induction with IPTG (3A). The CCLP band at 46.2kD became noticeably thicker, 
indicating that large quantities of CCLP were made. It is interesting to note that there is 
some of the “expressed” recombinant protein in the pre-induction sample (2A) indicating 
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that there was some “leaky” expression from the T7-promoter prior to induction of 
transcription. After centrifugation of the induced cells, the cell pellet was sonicated and 
centrifuged again to separate the soluble material from the insoluble. The resulting pellet 
(2B) and supernatant (3B) show that the bulk of CCLP has remained in the supernatant 
indicating that CCLP is soluble in aqueous solutions as we expected. Gel C shows the 
purity of this supernatant before (2C) and after (3C) heat treatment at 800C with 1mM 
Ca2+. Addition of calcium and heat treatment causes the normally clear solution of the 
post-sonication supernatant to turn milky as most of the proteins denature and precipitate. 
Fortunately, CCLP stayed in solution while other impurities were denatured and 
precipitated. Lane 3C is remarkably enriched in CCLP as the bacterial proteins 
precipitate, but impurities still remain. Lane 2D of Gel D shows the solution of the 
combined elution fractions that contained CCLP after HisTag chromatography was 
performed. The gel indicates that the sample is free from other protein contaminants after 
HisTag chromatography.  
 The results of SDS-PAGE analysis have shown that the expression and 
purification procedure described previously successfully expressed and purified CCLP in 
from BL21(DE3) E. Coli. Solution D of Figure 9 was then dialyzed into water and 
lyophilized, producing the solid shown in Figure 10. This lyophilized product will be 
used for future experimentation towards the modification of hydroxyl-containing residues 
with NSAID molecules. 
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UV spectra of CCLP in water indicate that the protein has a spectrum characteristic of a 
folded protein that contains both tyrosine and tryptophan residues. 
 
  
Figure 10: Solid CCLP Recovered via Lyophilization and UV Spectra of HisTag Eluent. 
 
[Right] UV visible spectra of CCLP post HisTag. A quartz cuvette with a pathlength of 
2mm was used. Absorbance indicates an approximate concentration of 47µM according 
to the Beer-Lambert law. [Left] Solid CCLP recovered from lyophilization was sent to 
the Watkins Laboratory for experimentation towards the modification of hydroxyl 
residues with NSAID molecules. 
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Experiment 2: Analysis of Binding of CCLP with M13 via Circular Dichroism 
Spectroscopy.  
Evidence provided by the CD spectra of CCLP under each condition, shown in 
Figure 11, suggests that the CCLP construct has retained its binding capabilities.  
 
Figure 11: CD Spectra of CCLP Under 
Various Conditions. 
 
CD spectra recorded between 200-
260nm on 50µM CCLP stock in SEC 
buffer. Confirmation of calcium binding 
in the CCLP construct can be seen in the 
signal change between apo and 1mM 
Ca2+ environments. EDTA was used to 
chelate unwanted Ca2+ in the apo 
sample. M13 alone gives random coil 
signal, Addition of M13 to CCLP in 
1mM Ca2+ increases the alpha helical 
signal and causes a disappearance of the 
random coil.  
 
Apo CCLP solution shows a double minima that is consistent with a alpha helical 
secondary structure, showing that the CCLP regions have retained the structure 
characteristic of the CaM components of the construct. Upon the addition of 1mM Ca2+, a 
change in signal can be seen, indicating that the CaM regions of CCLP successfully bind 
calcium. M13 peptide alone is unstructured as witnessed by the absence of helical or 
sheet structure in the solution with peptide alone. Upon the addition of Ca2+ and M13 
peptide to CCLP, the double minima shows an intensified signal. This is consistent with 
the fact that when bound to CaM, M13 assumes a helical shape. This intensification of 
alpha helix signal provides evidence that the CaM regions of CCLP construct 
successfully bind M13 peptide. 
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DISCUSSION 
The experiments reported here are on a novel, in-house designed protein that is 
one of the two components for a biomaterial whose purpose is to deliver anti-
inflammatory medications at the site of inflammation. The experiments reported here had 
two primary purposes. First, we had to evaluate and optimize a purification protocol for 
the protein from the bacterial contaminants of the expression system. Second, we had to 
ensure that the CaM component of the protein was still functional in its new context. 
Each of these two experiments will be discussed in turn. 
The expression and purification protocol of CCLP employed both standard and 
non-standard methods. The expression system that was used was designed to prevent 
leaky expression in order to avoid the synthesis of proteins that would be toxic to bacteria 
prior to induction23. We observed a band at the same MW as our product in the pre-
induction sample.  This band may be a protein at the same MW as our CCLP construct, 
or it may be actual CCLP that resulted from very low level transcription from the T7 
promoter. By comparison of the pre- and postinduction lanes, it was clear that the protein 
was not toxic to the cells since they continued to grow for two hours post induction. Post-
expression cells are known to contain soluble CCLP because the construct was present in 
the supernatant fraction post-sonication. Further, heat treatment of the supernatant is 
rarely employed in the purification of proteins because it causes proteins to precipitate, 
and precipitating protein can nucleate the precipitation of otherwise soluble proteins24. 
Due to CaM’s incredible resilience to denaturation especially in the presence of 
calcium20, it is able to withstand the extreme temperatures while almost of the bacterial 
proteins are permanently denatured and precipitate.  While HisTag chromatography has 
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been shown to work well with CCLP, an alternative chromatography method, phenyl 
sepharose chromatography, is an option for purification25. This method relies on the 
hydrophobic interaction of the CaM regions of CCLP with the stationary phase of the 
column. Once lyophilized, proteins are usually difficult to re-dissolve into aqueous 
solution. CCLP did so very easily, requiring no special efforts. In summary, the 
expression of CCLP and subsequent purification was very straightforward since the 
designed CCLP construct offers many of the same advantages that isolated CaM has. 
In contrast, the current PCLP construct has low solubility in aqueous 
environment. Since the M13 sequence is highly basic, and therefore hydrophilic, this 
implies that the CLS regions are highly insoluble. However, even with these hydrophobic 
CLS regions, the hydrophilicity of CaM dominates the CCLP construct, making it highly 
soluble. Both CCLP and PCLP are soluble in DMSO, which is a commonly used 
ingredient in topical medications with low cellular toxicity26. DMSO is known to affect 
the structure of proteins, however27. 
When CaM binds to M13, it induces a conformational change in M13 from 
random coil to helix. The change in CD spectra signal that accompanies this was shown 
by Blumenthal et al in 198528. The 220nm minima provides the most reliable data point 
because interference develops further into the UV spectrum. In Blumenthal’s study, the 
ellipticity of CaM+Ca2++M13 at 220nm was higher than the sum of M13 and CaM 
signals alone. This was due to the binding of CaM to M13 and the change of secondary 
structure that resulted. This same logic was followed when designing the CD study on 
CCLP, and the same observation was made.  
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Future experiments must be done towards covalently modifying the CCLP 
construct by esterification with Naproxen and Aspirin. and then determining whether the 
modified form retains its peptide binding capabilities. Solubility issues with the PCLP 
construct will also be addressed by altering its gene design. The CCLP construct is a 
promising candidate for the future development of this novel biomaterial.  
In conclusion, results show that we have successfully expressed and purified the 
CCLP construct in BL21(DE3) E. Coli and determined that the CaM regions of the CCLP 
construct have retained their peptide and calcium binding capabilities. As a parting 
comment for this body of work, we would like to report the first attempt to make a gel 
material from the PCLP and CCLP components. Austin Carroll, the student studying the 
PCLP portion of the project, and I mixed samples of CCLP and PCLP in DMSO. We 
then added Ca2+, and concentrated the solution. The result was a clear, viscous gel 
substance shown in Figure 12. Under the direction of Dr. Pedigo with the assistance and 
guidance of her graduate students, we have turned the concept of this biomaterial into a 
reality.  
 
Figure 12: CCLP and PCLP 
Gel Substance. 
 
This is an image of the gel 
substance formed upon the 
combination of CCLP and 
PCLP in DMSO with Ca2+. The 
formation of the gel was rapid 
(<1min). 
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